You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Regeneron, AZ partner on development of novel obesity drugs

Regeneron and AstraZeneca have announced a new collaboration focused on researching, developing and commercialising small molecule medicines targeting GPR75 for the treatment of obesity.